These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 21665227

  • 1. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients.
    Kerbrat A, Le Page E, Leray E, Anani T, Coustans M, Desormeaux C, Guiziou C, Kassiotis P, Lallement F, Laplaud D, Diraison P, Rouhart F, Sartori E, Wardi R, Wiertlewski S, Edan G.
    J Neurol Sci; 2011 Sep 15; 308(1-2):98-102. PubMed ID: 21665227
    [Abstract] [Full Text] [Related]

  • 2. Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland.
    Putzki N, Yaldizli O, Bühler R, Schwegler G, Curtius D, Tettenborn B.
    Eur Neurol; 2010 Sep 15; 63(2):101-6. PubMed ID: 20090344
    [Abstract] [Full Text] [Related]

  • 3. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.
    O'Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N.
    Neurology; 2011 May 31; 76(22):1858-65. PubMed ID: 21543733
    [Abstract] [Full Text] [Related]

  • 4. Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab.
    Baumgartner A, Stich O, Rauer S.
    Int J Neurosci; 2012 Jan 31; 122(1):35-9. PubMed ID: 21913869
    [Abstract] [Full Text] [Related]

  • 5. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L, Giannì C, Barletta V, Mancinelli C, Fubelli F, Borriello G, Pozzilli C.
    J Neurol Sci; 2012 Dec 15; 323(1-2):104-12. PubMed ID: 23006974
    [Abstract] [Full Text] [Related]

  • 6. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 Dec 15; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 7. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R, Quarantelli M, Bonavita S, Ventrella G, Lus G, Vacca G, Prinster A, Orefice G, Tedeschi G, Brescia Morra V.
    Acta Neurol Scand; 2012 Nov 15; 126(5):306-14. PubMed ID: 22107083
    [Abstract] [Full Text] [Related]

  • 8. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A, Bianchi MR, Deotto L, Benedetti MD.
    Eur Neurol; 2014 Nov 15; 72(3-4):173-80. PubMed ID: 25226868
    [Abstract] [Full Text] [Related]

  • 9. [Natalizumab (Tysabri) prescription practices of neurologists in southern France].
    Rocher F, Cohen M, Lebrun C.
    Rev Neurol (Paris); 2010 Apr 15; 166(4):412-8. PubMed ID: 19846185
    [Abstract] [Full Text] [Related]

  • 10. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis.
    Horga A, Castillo J, Rio J, Tintore M, Auger C, Sastre-Garriga J, Edo MC, Perez-Miralles F, Tur C, Nos C, Huerga E, Comabella M, Rovira A, Montalban X.
    Rev Neurol; 2011 Mar 16; 52(6):321-30. PubMed ID: 21387248
    [Abstract] [Full Text] [Related]

  • 11. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.
    Prosperini L, Giannì C, Leonardi L, De Giglio L, Borriello G, Galgani S, Pozzilli C, Gasperini C.
    Mult Scler; 2012 Jan 16; 18(1):64-71. PubMed ID: 21828195
    [Abstract] [Full Text] [Related]

  • 12. Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).
    Clerico M, Schiavetti I, De Mercanti SF, Piazza F, Gned D, Brescia Morra V, Lanzillo R, Ghezzi A, Bianchi A, Salemi G, Realmuto S, Sola P, Vitetta F, Cavalla P, Paolicelli D, Trojano M, Sormani MP, Durelli L.
    JAMA Neurol; 2014 Aug 16; 71(8):954-60. PubMed ID: 24977406
    [Abstract] [Full Text] [Related]

  • 13. MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis.
    Grimaldi LM, Prosperini L, Vitello G, Borriello G, Fubelli F, Pozzilli C.
    Mult Scler; 2012 Sep 16; 18(9):1337-9. PubMed ID: 22389413
    [Abstract] [Full Text] [Related]

  • 14. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
    Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J.
    Mult Scler; 2012 Jun 16; 18(6):899-901. PubMed ID: 22183929
    [Abstract] [Full Text] [Related]

  • 15. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.
    Rinaldi F, Perini P, Calabrese M, Rinaldi L, Gallo P.
    Mult Scler; 2009 Nov 16; 15(11):1359-62. PubMed ID: 19812116
    [Abstract] [Full Text] [Related]

  • 16. Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis.
    Arnal-Garcia C, García-Montero MR, Málaga I, Millán-Pascual J, Oliva-Nacarino P, Ramió-Torrentà L, Oreja-Guevara C.
    Eur J Paediatr Neurol; 2013 Jan 16; 17(1):50-4. PubMed ID: 23021975
    [Abstract] [Full Text] [Related]

  • 17. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP, Martín-Medina P, Berenguer-Ruiz L, Pérez-Carmona N, Sanchez-Perez R, Polache-Vengud J, Feliu-Rey E.
    Acta Neurol Scand; 2013 Aug 16; 128(2):e6-e10. PubMed ID: 23336398
    [Abstract] [Full Text] [Related]

  • 18. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R.
    Lancet Neurol; 2009 Mar 16; 8(3):254-60. PubMed ID: 19201654
    [Abstract] [Full Text] [Related]

  • 19. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
    N Engl J Med; 2006 Mar 02; 354(9):911-23. PubMed ID: 16510745
    [Abstract] [Full Text] [Related]

  • 20. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
    Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, Duquette P, Girard M, Pucci E, Lechner-Scott J, Slee M, Fernandez-Bolanos R, Grand'Maison F, Hupperts R, Verheul F, Hodgkinson S, Oreja-Guevara C, Spitaleri D, Barnett M, Terzi M, Bergamaschi R, McCombe P, Sanchez-Menoyo J, Simo M, Csepany T, Rum G, Boz C, Havrdova E, Butzkueven H, MSBase Study Group.
    Ann Neurol; 2015 Mar 02; 77(3):425-35. PubMed ID: 25546031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.